Don’t buy into whatever Conservatives for Lower Health Care Costs is trying to sell you on

Big Pharma Windfall – Conservatives for Lower Health Care Costs

Related:

Jon Tester Lost Senate Race And They’re Still Running Negative Ads Against Him

The ads trace back to a group called Conservatives for Lower Health Care Costs (CLHCC), which is registered in Delaware by the Corporation Trust Co. in Wilmington, Delaware. That company is a wholly owned subsidiary of Wolters Kluwer, a multi-national information services company based in the Netherlands with operations in more than 35 countries.

David Feider, a spokesman at Wolters Kluwer, said in an email that the company serves as the registered agent “for literally hundreds of thousands of businesses across the country.”

Read More »

Peace Train: Silencing contrarian voices

In the U.S., we proudly point to the First Amendment in the Bill of Rights that was adopted in 1791.

“Congress shall make no law respecting an establishment of religion, or prohibiting the free exercise thereof; or abridging the freedom of speech, or of the press; or the right of the people peaceably to assemble, and to petition the government for a redress of grievances.”

Peace Train: Silencing contrarian voices

Related:

U.S. Wars and Hostile Actions (WW2 – 2014)

Prescription Drug Price Reforms Won’t Happen for Years

Prescription Drug Price Reforms Won’t Happen for Years

The two biggest benefits for seniors in the IRA are the Medicare negotiation of certain high-cost prescription drugs, and the $2,000 out-of-pocket cap. But while price negotiations technically start next year, no consumer will see the benefit until the new prices begin in 2026, and even then on only 10 drugs (another 15 are added in 2027 and 2028, rising to 20 by 2029 and subsequent years).

The $2,000 out-of-pocket cap, which is across the board for all seniors, not just on certain drugs, is even worse. That cap doesn’t go into effect until 2025, although out-of-pocket costs get capped at $4,000 in 2024. If there is kind of an explanation for delays in setting up Medicare drug price negotiation, for the out-of-pocket cap there is not. You literally tally up patient out-of-pocket costs, which are fully transparent, until they hit $2,000, and then stop them. Why does this take more than two years to pull off? Medicare itself, the entire program, took only a year to implement.

Other parts of the bill do come online more quickly. The insulin price cap of $35 a month for Medicare recipients starts in 2023, as does free vaccine coverage in Medicare and the rebates on Medicare drugs with price increases above inflation. But the inflation rebate is benchmarked to 2021 prices, locking in those high costs, and just would mute price growth. The real benefits here are Medicare negotiations that lower drug prices, and the cap on all prescription drug costs for seniors. Those are delayed.

It is absolutely insane for a political party to boast that it lowered prices for seniors when the price reductions are years and years down the road. That kind of de facto bait and switch leads to distrust and anger. You’d have thought Democrats would have learned this lesson in the Affordable Care Act, whose major benefits didn’t kick in for four years after passage, a time lag that helped lead to two midterm wipeouts. But here we are again, as Democratic officials tout a drug price reform that isn’t visible to anyone.

That’s not necessarily Democrats’ fault (although they could have ignored the parliamentarian, of course). What is their fault is the failure to immediately make evident the benefits of the policy. Democrats have had a tendency to break faith with their base, to make promises and fail to deliver. Here’s a policy they’ve been promising for nearly two decades, they pass the policy, and they’re going to spend years explaining how the implementation is just around the corner. It comes off as double-talk and toxifies a political brand. And in this case, it was unnecessary.

Read More »

Will you get insulin-cost relief from the inflation bill? Not if you have private insurance

Will you get insulin-cost relief from the inflation bill? Not if you have private insurance

But an out-of-pocket cap identical to that for Medicare was stripped from the bill for those with private insurance because Democrats are trying to pass the bill by a simple majority through the reconciliation process. That requires Senate Parliamentarian Elizabeth MacDonough to vet the provisions. She said most of the health-related features were fine, but the insulin proposal for those who have private insurance, not Medicare, violated the Byrd provision, which says that issues “extraneous to the federal budget” cannot be passed by simple majority through reconciliation.

Out-of-pocket spending for those with Part D Medicare drug coverage will be capped at $2,000 a year.

In 2024, a 5% coinsurance payment that now kicks in after someone reaches the catastrophic drug spending level of $7,050 in Medicare will end. Because drug companies set their own prices, 5% on expensive drugs can be a lot of money.

Related:

Read More »

Manchin’s Climate Reversal Comes With Major Caveat: Expanding Oil and Gas

Conservative coal baron Sen. Joe Manchin (D-West Virginia) announced on Wednesday that he has come to an agreement with Democratic leaders for a reconciliation bill with key climate, prescription drug price and tax reforms — with a major caveat to expand oil and gas exploration.

Manchin’s Climate Reversal Comes With Major Caveat: Expanding Oil and Gas

Related:

Senate Dems reach draft deal to extend ACA premiums, lower drug costs

Also included in the Inflation Reduction Act — a bid to lower drug prices. Medicare will be allowed to negotiate the prices of some 10 pharmaceutical drugs in 2026, 15 more drugs in 2027 and 2028 and 20 more in 2029. In addition to price negotiation, the bill also imposes penalizing rebates on pharmaceutical manufacturers who hike drug costs above the rate of inflation starting next year.